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Abstract
Background: Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin’s lymphoma that rarely
metastasizes to the iris and the anterior segment. Blastic/pleomorphic morphology is thought to have an adverse
effect on prognosis in MCL. MCL is resistant to conventional chemotherapeutic regimens with a tendency for
multiple relapses. Management of anterior segment metastasis of systemic MCL has not been described in
literature.
Findings: A 58-year-old male presented with an aggressive, relapsing, metastatic, systemic blastic variant of MCL
with ocular involvement. At the time of initial presentation, large tumor cells were visible in the anterior chamber
(AC) along with hypopyon and fibrin. The AC cells stained positively for CD20. The iris was thickened and coated
with lymphoma cells. Iris neovascularization was present. Given extensive systemic and ocular involvement, the
patient was given combination chemotherapy with systemic ibrutinib and intravitreal injections of methotrexate
and rituximab. The disease response was monitored using multimodal imaging, including anterior segment optical
coherence tomography and ultrasound biomicroscopy. Following combination of systemic and intraocular
chemotherapy, there was a marked decrease in the ocular tumor load and the systemic disease.
Conclusions: Combination therapy with intravitreal injections of chemotherapeutic agents targeting monoclonal
B-cell population and novel systemic agents may help to achieve remission in anterior segment metastasis of
aggressive subtypes of NHL such as blastic variant of MCL. Multimodal imaging may assist in the management of
these cases.
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Findings
Introduction
Mantle cell lymphoma (MCL) is a rare subtype of
non-Hodgkin’s lymphoma (NHL) accounting for 6–
7 % of all NHL cases. Blastic/pleomorphic morphology
is thought to have an adverse effect on prognosis in
MCL. MCL is an aggressive form of NHL with poor
response to conventional therapy and risk of multiple
relapses [1, 2]. Systemic MCL can affect various organs
such as lymph nodes, bone marrow, spleen, and bowel
resulting in a poor median survival of 3–6 years after
diagnosis [3]. However, systemic metastases of NHL to
the eye are rare with most cases confined to the orbit
and adnexa [4]. Intraocular involvement is even rarer,
and it usually affects the choroid [5]. Thus, reports of
iris and anterior segment involvement due to metasta-
sis of systemic MCL have been limited to a few case
reports [6–8].
While radiation therapy has been used for the manage-
ment of orbit and adnexal involvement [9], intravitreal
injections of chemotherapeutic agents such as metho-
trexate (MTX) and rituximab (anti-CD20) have been
used for patients with vitreoretinal NHL [10, 11]. The
treatment for iris metastasis has not been well described
* Correspondence: quan.nguyen@unmc.edu
1Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center,
985540 Nebraska Medical Center, Omaha 68198-5540, NE, USA
Full list of author information is available at the end of the article
© 2015 Agarwal et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
Agarwal et al. Journal of Ophthalmic Inflammation and Infection  (2015) 5:30 
DOI 10.1186/s12348-015-0060-1
in literature. Ibrutinib is a novel Bruton’s tyrosine
kinase (BTK) inhibitor recently introduced for the
treatment of relapsed systemic MCL [12]. In this
index case report, multimodal imaging analysis of a
patient with anterior segment metastasis of relapsed
systemic MCL is described. Treatment outcome using
combination chemotherapy with systemic ibrutinib
and intravitreal injections of MTX and rituximab is
also discussed.
Case report
A 58-year-old Caucasian man was diagnosed with sys-
temic MCL, blastic variant, in August 2010. He received
six cycles of rituximab hyper-CVAD chemotherapy con-
sisting of alternating combinations of drugs (course A
and course B). Course A included cyclophosphamide,
vincristine, doxorubicin, and dexamethasone; course B
consisted of MTX and cytarabine [13]. Subsequently, the
patient received autologous stem cell transplantation
(ASCT) with BEAM chemotherapy [bis-chloroethylni-
trosourea (carmustine), etoposide, cytarabine, and mel-
phalan] in January 2012 [14]. Following ASCT, the
disease was in remission.
A routine restaging positron emission tomography
(PET) scan in January 2013 demonstrated relapse of the
disease with new, enlarged mediastinal lymph nodes. Bi-
opsy of a gluteal mass revealed metastatic MCL in
March 2013. The patient received six cycles of benda-
mustine plus rituximab salvage [15]. A repeat PET scan
in January 2014 did not show any disease activity.
In April 2014, the patient complained of redness, pain,
and milky white deposits in the right eye (OD). He was
diagnosed with anterior uveitis and elevated intraocular
pressure (IOP) and was started on topical prednisone
acetate 1 % (four times a day) along with pilocarpine 2 %
three times a day. He underwent trabeculectomy and an-
terior chamber (AC) paracentesis in August 2014. The
paracentesis sample was positive for CD20+ lymphoma
cells. PET scan demonstrated several areas of nodal and
extranodal disease (scalp mass and mediastinal nodes).
Cerebrospinal fluid (CSF) and bone marrow biopsy,
however, did not reveal lymphoma cells.
The patient presented to the Stanley M. Truhlsen Eye
Institute at the University of Nebraska Medical Center
in September 2014 with blurred vision, redness, and pain
in OD. Best-corrected visual acuity (BCVA) was count-
ing fingers at 3 m in OD and 20/20 in the left eye (OS).
A hypopyon of large tumor cells filled more than half of
the AC; large keratic precipitates were seen on the infer-
ior cornea. The iris was thickened and coated with
lymphoma cells. There was extensive neovascularization
of the iris (NVI). The angles were obliterated and the
AC was shallow (Fig. 1a). Anterior segment optical co-
herence tomography (AS-OCT) (Heidelberg Spectralis®,
Heidelberg, Germany) performed using the cornea proto-
col revealed large cells floating in the AC (Fig. 2a, b).
There was marked thickening of the iris of OD compared
to OS. Evaluation of the posterior segment with ultra-
sound B-scan demonstrated a clear vitreous cavity and ab-
sence of any retinochoroidal lesions. MRI revealed no
orbital, optic nerve, brain parenchymal, or meningeal
enhancement.
Due to the extensive ocular involvement and the
malignant morphology of the CD20-positive cells,
combination chemotherapy with intravitreal injections
of MTX (400 μg/0.1 ml) and rituximab (1 mg/
0.1 ml) were administered on two consecutive days.
Intravitreal ranibizumab (0.5 mg) was also adminis-
tered for the NVI. The oncologist initiated systemic
chemotherapy with ibrutinib 560 mg/day. A repeat
AC paracentesis was performed for cytological ana-
lysis, which revealed monoclonal B-cell lymphoma
population positive for CD20, CD5, cyclin D1, and
SOX11 but negative for CD10, CD3, and S100 (Fig. 3).
Fig. 1 a Slit-lamp photograph showing lymphoma involving the iris and anterior chamber (AC). There was diffuse conjunctival injection, a large
hypopyon, fibrin over the pupil, and iris neovascularization (especially nasally). b Slit-lamp photograph taken 2 weeks after initiation of treatment shows
a marked decrease in the conjunctival injection, AC inflammation, and hypopyon. The fibrin is no longer seen. Superior iridectomy and suture from
prior trabeculectomy are seen
Agarwal et al. Journal of Ophthalmic Inflammation and Infection  (2015) 5:30 Page 2 of 5
Ultrasound biomicroscopy (UBM) (Ellex Eye Cubed™,
Adelaide, Australia) findings were consistent with the
AS-OCT, showing iris thickening in OD compared to
OS (Fig. 4a, b).
At 1-week follow-up, BCVA improved to 20/50 in
OD. The hypopyon and iris neovascularization mark-
edly decreased. Evaluation of the posterior segment
with fluorescein angiography did not demonstrate any
abnormality. During the next 3 months, the patient
received two additional injections of intravitreal rituximab
at 6-week intervals and one additional injection of
MTX and ranibizumab 6 weeks after presentation
with interval improvement. AS-OCT demonstrated
marked decrease in the AC cells (Fig. 2c). The iris
thickening reduced following the combination chemo-
therapy (Fig. 4c–f ). Systemic lymphoma demonstrated
stabilization followed by improvement. Ibrutinib ther-
apy was tapered to 420 mg/day due to the concern of
secondary myelodysplastic syndrome and an episode
of neutropenic fever.
Fig. 2 a The anterior segment optical coherence tomography (AS-OCT) performed using the cornea protocol shows the presence of a large, irregular
hyper-reflective cellular material floating in the anterior chamber (AC). b shows the magnified view of the lymphoma cells. c The follow-up AS-OCT
scan shows a decrease in AC inflammation. d A single large granulomatous keratic precipitate is captured and its magnified view is shown
Fig. 3 a Photomicrograph of cell block showing cytological details of the anterior chamber fluid cells. a Hematoxylin and eosin (H&E) stain (100×)
demonstrates malignant lymphocytes. b Diff-Quik staining (100×) of the sample shows lymphoma cells with atypical, enlarged, irregular nuclei and
increased N/C ratio. c Immunostaining with CD3 (100×) shows negative staining of the lymphoma cells. d Immunostaining with pan-B cell marker
CD20 (100×) shows strong membranous staining. The findings on histopathology and the immunoprofile are consistent with the diagnosis of
mantle cell lymphoma
Agarwal et al. Journal of Ophthalmic Inflammation and Infection  (2015) 5:30 Page 3 of 5
Discussion
To the best of our knowledge, uveal metastasis of
MCL has been reported in only five cases in literature
thus far [6–8, 16, 17]. Among these cases, isolated in-
volvement of the anterior segment and iris was ob-
served in two cases [6, 7]. In a report by Economou
et al. [6], bilateral involvement of the iris was noted
in a 71-year-old male with large, reddish tumor-like
masses, anterior chamber inflammation, and hyphema.
Reid et al. [7] reported unilateral granulomatous
anterior chamber inflammation along with localized
undulations of the iris and presence of aberrant-
appearing vasculature in an elderly male with sys-
temic MCL. The diagnosis of intraocular MCL was
confirmed using cytopathology in only one case by
Economou et al. [6]. In all these case reports, the
management of secondary iris lymphoma was limited
to frequent topical steroids, systemic chemotherapy,
or external beam radiation. Since the description of
these cases, numerous systemic and local ocular che-
motherapeutic strategies have evolved in the manage-
ment of aggressive relapsing tumors with secondary
ocular metastasis. The use of intravitreal chemother-
apy along with systemic anti-cancer agents has not
been described for the treatment of iris metastasis of
MCL or other types of NHL.
Concurrent treatment with intravitreal MTX and ri-
tuximab has been successfully employed in the manage-
ment of vitreoretinal NHL with few adverse events and
remission achieved in more than two third of cases [10].
Similarly, for systemic therapy in NHL, rituximab is
often combined with other chemotherapeutic agents
given its anti-CD20 activity. In this case, we used intra-
vitreal injections of both MTX and rituximab due to the
extensive tumor load.
Ibrutinib has been approved by the United States Food
and Drug Administration (US-FDA) for the treatment of
MCL in patients who have received at least one prior
therapy [12]. In our patient, chemotherapy with ibrutinib
resulted in marked decrease in the systemic metastatic
foci of MCL. However, the exact role of ibrutinib in re-
ducing the ocular tumor load remains unclear.
UBM and AS-OCT complement each other in the
diagnosis and management of non-pigmented iris tu-
mors [18]. These techniques produce high-resolution
images of the iris tumors resulting in excellent
visualization of the tumor anatomy and measurement of
tumor dimensions. Careful evaluation of morphological
features of the iris on UBM and AS-OCT enabled effect-
ive monitoring of the treatment response in our patient
(Figs. 2 and 4). To the best of our knowledge, the ap-
pearance of lymphoma cells on AS-OCT has not been
Fig. 4 a Ultrasound biomicroscopy (UBM) of the right eye shows secondary angle closure due to thickened iris. b UBM of the left eye shows
normal appearance of the iris of the fellow eye with open angles. CB indicates the ciliary body. c AS-OCT of the right eye shows the pre-treatment state
of the temporal iris. The white arrow indicates the floating lymphoma cells. The angle of the AC appears closed. d The appearance of the iris
after institution of therapy reveals a decrease in the thickness and opening up of the angle (double-sided arrow). e The nasal iris shows partially visible
posterior surface of the iris and internal hypo-reflectivity (asterisk) due to the increased tissue density anteriorly and poor penetration of the infrared
rays through the thick iris. f The follow-up scan of the nasal iris after treatment shows reduction in the thickness and clearly visible posterior iris surface.
The angle of AC appears open (double-sided arrow)
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characterized (Fig. 2). In this case, multimodal imaging
allowed an objective assessment of reduction in the
tumor load.
Conclusions
The index case describes successful initial management
of anterior segment ocular metastasis in MCL with com-
bined systemic and local ocular chemotherapeutic
agents. The treatment regimen may be individualized;
results on flow cytometry may guide the selection of ap-
propriate pharmacologic agents after AC paracentesis.
Iris metastasis can be well visualized using both UBM
and AS-OCT, enabling serial objective assessments of
the response to chemotherapy.
Consent to publish
The consent to publish has been obtained from the par-
ticipant to report individual patient data.
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